Gene
MDM2
MDM2 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (68), Actionable biomarkers (2), Trial mentions (73), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MDM2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 10 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 4 of 8,875 | 0.05% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 7 of 8,275 | 0.08% | 29 of 11,460 | 0.25% |
| 2022 | 6 of 8,285 | 0.07% | 32 of 13,598 | 0.24% |
| 2021 | 13 of 8,692 | 0.15% | 44 of 15,045 | 0.29% |
| 2020 | 6 of 7,640 | 0.08% | 33 of 14,459 | 0.23% |
| 2019 | 11 of 7,300 | 0.15% | 43 of 12,159 | 0.35% |
| 2018 | 8 of 6,927 | 0.12% | 24 of 11,854 | 0.20% |
| 2017 | 1 of 6,558 | 0.02% | 36 of 11,595 | 0.31% |
Showing 10 of 37 years.
Assay-provider ledger (68)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Ambion | Reagent supplier | Clinical validation | 1 | December 26, 2025 |
| BIO-RAD Laboratories S.A. (trypan blue) | Reagent supplier | Clinical validationAnalytical validation | 2 | December 26, 2025 |
| Biolabmix | Reagent supplier | Clinical validation | 1 | December 26, 2025 |
| Pan-Eco | Reagent supplier | Clinical validation | 1 | December 26, 2025 |
| ThermoFisher Scientific | Reagent supplier | Clinical validation | 1 | December 26, 2025 |
Showing 5 of 68 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MDM2 amplification | CISPLATIN | responsive | germ cell tumor | Cancer Genome Interpreter |
| MDM2 amplification | Mdm2 Inhibitors | response-associated | liposarcoma | Cancer Genome Interpreter |
Trial mentions (73)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06952400 | Trial biospecimen (AACT) |
| NCT04785196 | Trial eligibility (AACT) |
| NCT05800340 | Trial eligibility (AACT) |
| NCT02579824 | Trial eligibility (AACT) |
| NCT03836066 | Trial eligibility (AACT) |
Showing 5 of 73 trial mentions.
Target-disease associations (639)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| AMED syndrome, digenic | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| APC-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adult-onset autosomal recessive sideroblastic anemia | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 639 associations.
Vendor sourcing (216)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Affiliated Hospital of Qingdao University | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically proven primary high-risk Retroperitoneal sarcoma(RPS) (Including Dedifferentiated liposarcoma (DDLPS), leiomyosarcoma(LMS), Undifferentia... | View trial NCT05844813 |
| Affiliated Hospital of Qingdao University | Trial collaborator | Mentioned in trial textTrial free-text mention | MDM2 | View trial NCT05844813 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.919G>A (p.D307N) alteration is located in exon 11 (coding exon 11) of the MDM2 gene. This alteration results from a G to A substitution at nucleotide p... | View ClinVar record SCV003646663.2 |
| Anticancer Fund, Belgium | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis. * ... | View trial NCT04031677 |
| Anticancer Fund, Belgium | Trial collaborator | Mentioned in trial textTrial free-text mention | MDM2 | View trial NCT04031677 |
Showing 5 of 216 sourcing records.
Trial-cited literature (427)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Precision Medicine Program in Chinese Pediatric Patients With Sarcoma. | JCO precision oncology | 2026 | 0 |
| Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia. | Blood | 2025 | 9 |
| Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases. | Annals of oncology : official journal of the European Society for Medical Oncology | 2025 | 8 |
| Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | 6 |
| Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study. | Targeted oncology | 2025 | 2 |
Showing 5 of 427 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.R71Q | 1 | 2010 | PMID 20960466 |
| p.T469S | 2 | 2010 to 2016 | PMID 27370570, PMID 20138542 |
| p.V157G | 1 | 2010 | PMID 20145180 |
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| METFORMIN | Chemical | negative_correlate |
Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. | 2019 |
| Emetine Hydrochloride | Chemical | negative_correlate |
Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus. | 2016 |
| TELMISARTAN | Chemical | negative_correlate |
Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. | 2013 |
| Valproic Acid | Chemical | negative_correlate |
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. | 2012 |
| MELATONIN | Chemical | associate |
Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells. | 2010 |
Showing 5 of 61 relation assertions.
Organizations publishing (417)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 32 | 2003 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 26 | 2011 to 2025 |
| Dana-Farber Cancer Institute | Other | 16 | 2011 to 2023 |
| Government of the United States of America | Government | 15 | 2010 to 2023 |
| Harvard Medical School | Academic | 13 | 2010 to 2023 |
Showing 5 of 417 organizations.
Where MDM2 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
569 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.